• Incannex posted a new release: screening has started in the DReAMzz Phase 2 dose-confirmation trial of IHL-42X for obstructive sleep apnea.
• IHL-42X holds FDA Fast Track status; results are intended to support planned Phase 3 development.
• Prior Phase 2 data showed up to 83% reduction in AHI, with improvements in patient-reported outcomes.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Incannex Healthcare Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607230800PRIMZONEFULLFEED9765859) on July 23, 2026, and is solely responsible for the information contained therein.